Calypte Biomed! Marktkapitalisierung 1 Mio $ !

Die Produktion des HIV Schnelltests sei bereits angelaufen und für das Testverfahren zum Nachweis von Leberfunktionsstörungen besitze Calypte in den USA das alleinige Recht zur Vermarktung an sämtliche Versicherungsunternehmen, welche den Schnelltest zur Risikoabschätzung beim Abschluss von Lebensversicherungen und Invaliditätspolicen nutzen würden. Bei jährlich 6 bis 8 Millionen neuen Versicherungsnehmern in den USA dürfte Calypte also schon bald ein Multi-Millionendollar-Markt ins Haus stehen.

Beim aktuellen Aktienkurs verfüge die Gesellschaft über eine Marktkapitalisierung von nur 18 Mio. US-Dollar, die Aktie sollte also noch reichlich Spielraum nach oben haben. Kurzfristig könnte es nach dieser Rallye zwar auch wieder einen kleinen Pullback oder zumindest eine Seitwärtsbewegung geben, doch angesichts der aktuellen Fakten, sollte der Titel langfristig in Richtung Norden laufen.

Anleger, die nach diesen Ausführungen nun auch mit einem Engagement in Calypte liebäugeln würden, sollten eines bedenken, trotz aller Prognosen könne bei Calypte, das ja über keinerlei Reserven verfüge, noch einiges schief gehen. Man sollte daher seinen Einsatz eher als Spielgeld sehen, entweder man verliere alles oder vervielfache seinen Einsatz. Und bei einem Kurs von 0,38 US-Dollar könne man, ohne ein Vermögen zu verlieren, schon einmal richtig in die Vollen greifen.

Nach Ansicht der Analysten von "Der Aktionär-online" ist die Calypte Biomed-Aktie ein interessantes Investment.

The company is currently in the process of implementing the new product package inserts, the Subject Information Brochure and other associated labeling materials. "We believe that the FDA's action is very significant in that it should facilitate our ability to market our tests to clinics and testing centers throughout the U.S.," stated Nancy Katz, Calypte's President and Chief Executive Officer. "It has been one of our continuing goals to provide products that allow more people to be tested in easier, less painful ways. FDA's recent approvals to revise our product labeling to encourage broader use of our products facilitates our ability to accomplish this critical goal."

About Calypte Biomedical:

Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found at www.calypte.com.

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC.


   CONTACT: Calypte Biomedical Corporation
            Don Kafader, 510/749-5130
            dkafader@calypte.com
             or
            Investor Relations Contact:
            Sitrick & Company
            Joe Bunning, 310/788-2850
            joe_bunning@Sitrick.com

   SOURCE: Calypte Biomedical Corporation